Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Pulmonary hypertension and pregnancy:
risks, counseling and management

Pregnancy in women with pulmonary arterial hypertension is a high-risk condition. The increase in blood volume and cardiac output required during pregnancy may strain a right ventricle already pumping against elevated pulmonary vascular resistance. Although outcomes have improved compared with the past, maternal mortality in PAH remains significant in contemporary series, and the 2025 ESC guidelines consider multidisciplinary counseling before conception essential.
The risk is not the same for everyone: PAH severity, right ventricular function, risk profile and disease subtype profoundly affect prognosis.

A woman with pulmonary arterial hypertension who wishes to become pregnant should therefore not stop contraception or medications on her own. The decision should be discussed with an expert pulmonary hypertension center and a Pregnancy Heart Team.

The main points to know are:


Why pregnancy can be dangerous in PAH

During pregnancy, plasma volume and cardiac output progressively increase. In the normal circulation, vascular resistance adapts; in PAH, the right ventricle may be unable to adequately increase output against an abnormally resistant pulmonary vascular bed. This may lead to right ventricular dilatation and failure, systemic hypotension and reduced organ perfusion.

The 2022 ESC guidelines reported maternal mortality of 11–25% in more recent series, far below historical figures but still high. The 2025 ESC pregnancy guidelines confirm the same range and emphasize that there is no pulmonary pressure threshold below which pregnancy can be considered risk-free.
Severe forms, non-vasoreactive idiopathic PAH and Eisenmenger syndrome carry the highest risk. Better outcomes have been reported in mild and well-controlled forms, but individual assessment remains essential.

In patients with pulmonary hypertension associated with congenital heart disease, risk also depends on anatomy and the presence of shunts. Eisenmenger syndrome is among the highest-risk conditions for right heart failure, hypoxemia and paradoxical embolism.

Before pregnancy: counseling and contraception

The best time to address these issues is before conception. Counseling should explain maternal, fetal and neonatal risks, potential changes to treatment and reproductive alternatives. Genetic counseling may also be appropriate in heritable forms.
The 2025 guidelines recommend that women with PAH who wish to become pregnant be assessed by a multidisciplinary team and participate in a shared decision-making process.

Contraception should be discussed at the time of diagnosis in women of childbearing age. Several effective options are available, but the choice depends on preferences, thrombotic risk, ongoing treatment and clinical status. Intrauterine devices and long-acting implants may offer high efficacy; with bosentan, the possible reduction in efficacy of certain hormonal contraceptives must be considered.
Emergency contraception may be used when indicated, whereas any invasive procedures must take anesthetic and cardiovascular risks into account.

If pregnancy has already begun: what happens next?

When a woman with PAH discovers that she is pregnant, promptly contacting the specialist center is important. All treatments should not be stopped abruptly: some medications must be discontinued or replaced, while others are needed to prevent disease deterioration.
Continuing or terminating the pregnancy must be discussed on an individual basis. The 2025 ESC guidelines state that termination should be discussed when pregnancy occurs and recommend that, if chosen, it be performed at a center experienced in pulmonary hypertension.

The 7th World Symposium on Pulmonary Hypertension in 2024 further emphasized shared decision-making: some women with mild, well-controlled disease may have favorable outcomes with multidisciplinary care, whereas the risk of complications is particularly high in patients with severe or poorly controlled PH and in those with Eisenmenger syndrome, and pregnancy is strongly discouraged.

If pregnancy continues, monitoring becomes more intensive. The frequency depends on the stage of pregnancy and disease severity. Assessment includes symptoms, echocardiography and BNP or NT-proBNP. An unusual increase in dyspnea or new fluid retention during the first two trimesters should be regarded as warning signs.

Which medications must be reviewed during pregnancy?

PAH treatment requires immediate review. The 2025 ESC guidelines state that endothelin receptor antagonists, riociguat and selexipag are not recommended during pregnancy because of potential or undetermined teratogenicity. For the endothelin receptor antagonist class, this includes medications such as bosentan, ambrisentan and macitentan.
Discontinuation and substitution must be arranged by the specialist center rather than undertaken independently.

When clinically necessary, phosphodiesterase type 5 inhibitors and prostacyclin analogues may be used during pregnancy under specialist supervision. Sildenafil is among the most widely used medications in published series; in more severe forms, it may be combined with prostacyclin treatment. Patients with a true positive response to vasoreactivity testing who are well controlled on calcium channel blockers may continue that treatment as directed by a specialist.

Diuretics may be necessary in the presence of heart failure and fluid retention. Oxygen is used when hypoxemia is present, with particular attention to maternal and fetal oxygenation. Anticoagulation, however, is not automatically prescribed to all women with PAH: the indication and choice of agent depend on thromboembolic risk and the clinical context.

Delivery and postpartum: why planning is essential

Delivery should be planned at an experienced center, involving cardiology or pulmonology specialists experienced in PH, obstetrics, anesthesia, intensive care and neonatology. The mode and timing of delivery are chosen individually. Contemporary guidelines generally favor regional anesthetic techniques over general anesthesia when appropriate, but the decision depends on the specific clinical circumstances.

The postpartum period is one of the most dangerous periods. After delivery, rapid changes in circulating volume and venous return may precipitate right ventricular failure. The 2025 ESC guidelines emphasize that a substantial proportion of maternal events occur after birth and that women remain vulnerable beyond the immediate puerperium.
Monitoring therefore does not end with delivery. Severe forms may require intensive surveillance, careful fluid balance and immediate optimization of PAH treatment.

Breastfeeding should also be discussed in relation to the medications needed after delivery. When disease is severe or complications have occurred, the priority is to optimize maternal treatment promptly, even if this makes breastfeeding incompatible with certain treatments.

Frequently asked questions about pulmonary hypertension and pregnancy

Is pregnancy possible with pulmonary arterial hypertension?
Pregnancy in PAH carries a very high maternal and fetal risk and should be discussed before conception with an experienced multidisciplinary team. Risk varies with disease severity, right ventricular function and disease control.

What should you do if you discover you are pregnant while living with PAH?
An expert center for pulmonary hypertension and pregnancy should be contacted promptly. Risks, medications and options, including continuing or terminating the pregnancy, must be reassessed through shared decision-making.

Which PAH medications are not recommended during pregnancy?
The 2025 ESC guidelines state that endothelin receptor antagonists, riociguat and selexipag are not recommended during pregnancy because of potential or undetermined teratogenicity.

Which treatments can be used during pregnancy?
When pregnancy continues, phosphodiesterase type 5 inhibitors and prostacyclin analogues may be used under specialist care; calcium channel blockers may be continued in appropriately selected patients with a true positive vasoreactivity response.

Does the risk end after delivery?
No. The postpartum period is particularly critical because rapid hemodynamic changes may precipitate right ventricular failure. Planned intensive monitoring is required after delivery as well.

References
  1. De Backer J, Haugaa KH, Hasselberg NE, et al. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. European Heart Journal. 2025;46(43):4462-4568. doi:10.1093/eurheartj/ehaf193.
  2. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237.
  3. Preston IR, Howard LS, Langleben D, et al. Management of pulmonary hypertension in special conditions. European Respiratory Journal. 2024;64(4):2401180. doi:10.1183/13993003.01180-2024.
  4. Olsson KM, Channick R. Pregnancy in pulmonary arterial hypertension. European Respiratory Review. 2016;25(142):431-437.
  5. Bedard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? European Heart Journal. 2009;30(3):256-265. doi:10.1093/eurheartj/ehn597.
  6. Jais X, Olsson KM, Barbera JA, et al. Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. European Respiratory Journal. 2012;40(4):881-885. doi:10.1183/09031936.00141211.
  7. Kiely DG, Condliffe R, Webster V, et al. Improved survival in pregnancy and pulmonary hypertension using a multiprofessional approach. BJOG. 2010;117(5):565-574. doi:10.1111/j.1471-0528.2009.02492.x.
  8. Bonnin M, Mercier FJ, Sitbon O, et al. Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology. 2005;102(6):1133-1137.
  9. Sliwa K, van Hagen IM, Budts W, et al. Pulmonary hypertension and pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac Disease (ROPAC) of the European Society of Cardiology. European Journal of Heart Failure. 2016;18(9):1119-1128. doi:10.1002/ejhf.594.
  10. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2016;37(1):67-119. doi:10.1093/eurheartj/ehv317.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.